Author

Shireen S. Ganapathi

University of WashingtonORCID 0000-0002-1239-2166Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Elizabeth R. LawloriD· 2 shared Nicolas M. GarciaiD· 2 shared Aaron K OlsoniD· 1 shared Aya MiyakiiD· 1 shared Darleen S. Tu· 1 shared Emma D. WrenniD· 1 shared Erolcan SayariD· 1 shared Harini SadeeshkumariD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Elizabeth R. LawlorORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyPediatric Blood & CancerPeer-reviewedNov 26, 2025

Determining preclinical safety of Aclarubicin in pediatric malignancies

Darleen S. Tu, Aaron K Olson, Kimberly S. Waggie…·Shireen S. Ganapathi

This study evaluates Aclarubicin's safety and efficacy in pediatric cancer models, finding it effective with reduced genotoxicity and cardiotoxicity compared to doxorubicin.

DOI 10.1002/pbc.32169

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 2, 2025

Transcriptional Rewiring of BET Inhibitor Treated Ewing Sarcoma Cells Augments their Dependency on Focal Adhesion Kinase

Shireen S. Ganapathi, Emma D. Wrenn, Nicolas M. Garcia…·Elizabeth R. Lawlor

This study shows that BET inhibitor treatment rewires Ewing sarcoma transcription, increasing dependency on FAK, and that combining BET and FAK inhibitors synergistically reduces tumor growth.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky